In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Wheat waste reworked into pulp alternative
In Washington state, Columbia Pulp is looking to convert wheat straw into a higher-value products, such as toilet paper and takeout food boxes, that...
Mango-based bioplastic eyed as PET alternative
At Mexico’s National Polytechnic Institute (IPN), students have developed a bioplastic based on mango peel that could be used to produce bottles, cutlery, plates,...
University team converts waste into polymeric ash for concrete replacement
In Mexico, researchers have created a cement alternative using waste materials from paper recycling, coal, marbling, sugarcane ash, and unicel industries.
The work, led by...